J. Gueudry
University of Rouen
OphthalmologyInternal medicineSurgeryPathologyDermatologyRetrospective cohort studyChemistryProspective cohort studyMesenchymal stem cellCorneal endotheliumUveitisCorneaSymblepharonCannulaVisual acuityKeratitisBone marrowWound healingMacular edemaAcanthamoeba keratitisToxic epidermal necrolysisVoriconazoleConjunctival EpitheliumEndothelial cell densityAcanthamoeba polyphagaTransplantationRabbit modelRefractoryMedicineBiologyMicrobiologyPharmacology
25Publications
4H-index
136Citations
Publications 26
Newest
#1J. GueudryH-Index: 4
#2Nicolas GirszynH-Index: 7
view all 3 authors...
Introduction Les uveites non-infectieuses sont responsables de 5 a 20 % des cas de cecite legale dans les pays developpes. Ce pronostic est secondaire a l’apparition de complications oculaires (œdeme maculaire, vascularite, glaucome), a l’origine de sequelles anatomiques irremediables. L’adalimumab, un anticorps monoclonal anti-TNF alpha, a montre son efficacite dans le controle de l’inflammation intra-oculaire au cours des deux etudes prospectives VISUAL I et II [1] . Cependant, le taux de rech...
Source
Introduction L’œdeme maculaire (OM) est une complication frequemment rencontree au cours des uveites non-infectieuses non-anterieures [1] . L’apparition d’un OM serait responsable d’une baisse d’acuite visuelle chez un tiers des patients souffrant d’une uveite posterieure [2] . Une prise en charge therapeutique adaptee et precoce est necessaire pour eviter l’apparition de sequelles visuelles permanentes. Les recommandations therapeutiques actuelles concernant la prise en charge de l’OM reposent ...
Source
Introduction La vascularite retinienne (VR) correspond a une inflammation des vaisseaux retiniens arteriels, veineux ou capillaires, pouvant aboutir a une occlusion vasculaire et une ischemie retinienne. Le but de notre etude etait d’evaluer l’efficacite des anti- TNF alpha et des anti-IL6 recepteur dans la prise en charge des vascularites retinienne. Patients et methodes Il s’agit d’une etude retrospective descriptive nationale multicentrique ayant pour but d’evaluer l’efficacite therapeutique ...
Source
#1Mathilde LeclercqH-Index: 3
#2V. LangloisH-Index: 4
Last. J. Gueudry (University of Rouen)H-Index: 4
view all 8 authors...
Abstract Objective To compare the efficacy and safety of Disease-modifying antirheumatic drugs (DMARDs) and anti-TNF-α agents in patients with non-infectious non-anterior uveitis. Methods Single center retrospective study including adult patients with non-infectious intermediate, posterior or pan-uveitis. Outcomes were compared between patients treated with DMARDs or anti-TNF-α agents. The primary outcome was treatment failure or occurrence of serious adverse events. Treatment failure was determ...
Source
#1J. Gueudry (University of Rouen)H-Index: 4
#2Laetitia Le Goff (University of Rouen)H-Index: 5
Last. Loïc Favennec (University of Rouen)H-Index: 27
view all 10 authors...
Purpose/Aims: Infectious keratitis is a major cause of visual impairment and blindness worldwide. Common difficulties in treating fungal keratitis prompt new therapeutic possibilities. In this study, intrastromal voriconazole and posaconazole, and topical posaconazole, were tested for their potential to obtain therapeutic cornea concentrations.Materials and Methods: Pharmacokinetics of triazole intracorneal/eye drop administration was studied in rats. Sixty-two rats were treated either by vorico...
Source
#2V. LangloisH-Index: 4
Last. J. GueudryH-Index: 4
view all 5 authors...
Introduction Les uveites non-infectieuses non-anterieures representent une cause majeure de cecite dans les pays industrialises. Aujourd’hui, en cas de rechute sous corticotherapie ou de corticodependance, l’intensification therapeutique repose sur les immunosuppresseurs conventionnels (methotrexate, mycophenolate mofetil ou azathioprine). Cependant, avec l’emergence des biotherapies (anti-TNF alpha et anti-recepteur a l’IL-6), la strategie therapeutique actuelle est en train de se redefinir. Ma...
Source
#1J. Gueudry (University of Rouen)H-Index: 4
#2Laetitia Le Goff (University of Rouen)H-Index: 5
Last. Loïc Favennec (University of Rouen)H-Index: 27
view all 12 authors...
Background: Acanthamoeba keratitis (AK) is a sight-threatening infectious disease. Its effective and safe medical therapy remains highly debated. Recently, voriconazole, a monotriazole with noted in vitro activity against a large variety of fungi, has been successfully used both topically and systemically to treat human AK cases. Objectives: To measure anti-Acanthamoeba polyphaga in vitro activity, anti-rat AK efficiency and rat cornea penetration of eye-drop and oral voriconazole. Methods: A. p...
Source
#1Mathilde LeclercqH-Index: 1
#2M Le BesneraisH-Index: 1
Last. J. GueudryH-Index: 4
view all 9 authors...
Biotherapies appear as potential drugs for the treatment of inflammatory noninfectious uveitis. In this report, we show that tocilizumab, an anti-IL-6 agent, greatly improved two patients with birdshot chorioretinopathy refractory to conventional immunosuppressive drugs, interferon α2a, and anti-TNFα agents. After a follow-up of 22 months, patients exhibited an improvement of both visual acuity and macular edema. A corticosteroid-sparing effect was achieved in both cases.
Source
#1J. GueudryH-Index: 4
#2L. Le Goff (University of Rouen)H-Index: 4
Last. Marc MuraineH-Index: 17
view all 10 authors...
Purpose Acanthamoeba keratitis is a sight-threatening infectious disease. Its effective and safe medical therapy remains highly debated. The aim of this study is to test in vitro and in vivo voriconazole as a potential antiamoebic treatment for Acanthamoeba keratitis. Methods In vitro sensitivity of Acanthamoeba polyphaga to voriconazole was assessed using a commercially available viability assay. In vivo, Sprague-Dawley male rats were injected in the left cornea stromal layer with trophozoites....
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.